In this non-partnered program, we developed CLR-TS for targeted delivery of antivirals (TargoVir™) to eradicate intracellular viral reservoirs in the form of infectious virions and/or proviral DNA integrated into the host cell’s genome.


While no treatments are currently available for clearing such reservoirs, our approach is intended to completely eradicate these pathogens; this may for the first time enable curative treatments for such chronic infections. In addition, because of the multimodal effect of the active compound RBT-05, this treatment may clear viral co-infections that further worsen the patients’ prognoses.

TargoVir™ is constructed with the CLR-TS, encapsulating the antiviral and virucidal compound RBT-05, a carbohydrate binding agent (CBA) that attaches to surface glycans on the viral envelope, allowing it to inactivate a broad range of viral pathogens. These include the hepatitis viruses HBV, HCV and HDV, the human immunodeficiency virus, type 1 (HIV-1), as well viruses with considerable epidemic risk potential such as the Ebola and Marburg viruses.


TargoVirTM: Production and Verification of a Highly Innovative Broad-Spectrum Virostatic In Vivo
This project was supported by the European Regional Development Fund (ERDF). Our explorative nanomedicine product TargoVirTM has proven to be very effective against various human pathogenic viruses of high medical relevance (e.g., HIV, several hepatitis viruses) or high outbreak potential (such as the Ebola viruses). With its exclusive mechanism of action, TargoVirTM has a USP, as it can inhibit the infectivity of both intra- as well as extracellular viruses.

Back To Top